Second-line tests in the differential diagnosis of neoplastic and non-neoplastic hypercortisolism: a systematic review and meta-analysis
Open Access
- 20 April 2023
- journal article
- review article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 46 (10) , 1947-1959
Abstract
Purpose: The clinical and hormonal overlap between neoplastic (CS) and non-neoplastic (NNH/pCS) hypercortisolism is a challenge. Various dynamic tests have been proposed to allow an early discrimination between these conditions, but to date there is no agreement on which of them should be used. Aim: To provide an overview of the available tests and to obtain a quantitative synthesis of their diagnostic performance in discriminating NNH/pCS from CS. Methods: The included articles, published between 1990 and 2022, applied one or more second line tests to differentiate NNH/pCS from CS patients. For the NNH/pCS group, we admitted the inclusion of patients presenting clinical features and/or biochemical findings suggestive of hypercortisolism despite apparent lack of a pCS-related condition. Results: The electronic search identified 339 articles. After references analysis and study selection, we identified 9 studies on combined dexamethasone-corticotropin releasing hormone (Dex-CRH) test, 4 on Desmopressin test and 3 on CRH test; no study on Dex-Desmopressin met the inclusion criteria. Dex-CRH test provided the highest sensitivity (97%, 95 CI% [88%; 99%]). CRH tests showed excellent specificity (99%, 95% CI [0%; 100%]), with low sensitivity. Although metaregression analysis based on diagnostic odds ratio failed to provide a gold standard, CRH test (64.77, 95% CI [0.15; 27,174.73]) seemed to lack in performance compared to the others (Dex-CRH 138.83, 95% CI [49.38; 390.32] and Desmopressin 110.44, 95% CI [32.13; 379.63]). Discussion: Both Dex-CRH and Desmopressin tests can be valid tools in helping discrimination between NNH/pCS and CS. Further studies are needed on this topic, possibly focusing on mild Cushing’s Disease and well-characterized NNH/pCS patients. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022359774, identifier CRD42022359774.Keywords
Funding Information
- Università degli Studi di Padova
This publication has 35 references indexed in Scilit:
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing’s disease and pseudo-Cushing state: a comparative studyClinical Endocrinology, 2011
- Concomitant Medication Use Can Confound Interpretation of the Combined Dexamethasone-Corticotropin Releasing Hormone Test in Cushing’s SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2009
- Severe Obesity Confounds the Interpretation of Low-Dose Dexamethasone Test Combined with the Administration of Ovine Corticotrophin-Releasing Hormone in Childhood Cushing SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2008
- The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing's syndromeEuropean Journal of Endocrinology, 2008
- The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2008
- Utilization of the PICO framework to improve searching PubMed for clinical questionsBMC Medical Informatics and Decision Making, 2007
- The dexamethasone‐suppressed corticotropin‐releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo‐Cushing's statesClinical Endocrinology, 2007
- Comparison of the Dexamethasone-Suppressed Corticotropin-Releasing Hormone Test and Low-Dose Dexamethasone Suppression Test in the Diagnosis of Cushing’s SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2006
- Corticotropin-Releasing Hormone Stimulation Following Low-Dose Dexamethasone AdministrationJAMA, 1993